Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
Lead Sponsor:
Pfizer
Conditions:
Acne Inversa
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This i...
Eligibility Criteria
Inclusion
- male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa
Exclusion
- History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
- Infected with hepatitis B or hepatitis C viruses.
- Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
Key Trial Info
Start Date :
December 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2022
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT04092452
Start Date
December 2 2019
End Date
January 10 2022
Last Update
June 15 2023
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
The University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35233
2
The University of Alabama at Birmingham Hospital Outreach Lab
Birmingham, Alabama, United States, 35249
3
The University of Alabama at Birmingham Investigation Drug Services Pharmacy
Birmingham, Alabama, United States, 35249
4
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294